Can we avoid high levels of dose escalation for high-risk prostate cancer in the setting of androgen deprivation?

by Shakespeare TP, Wilcox SW, Aherne NJ
Published 2016-05-01

Can we avoid dose escalation for intermediate-risk prostate cancer in the setting of short-course neoadjuvant androgen deprivation?

by Shakespeare TP, Wilcox SW, Aherne NJ
Published 2016-03-01

Long-term outcomes from dose-escalated image-guided intensity-modulated radiotherapy with androgen deprivation: encouraging results for intermediate- and high-risk prostate cancer

by Wilcox SW, Aherne NJ, Benjamin LC, Wu B, de Campos Silva T, McLachlan CS, McKay MJ, Last AJ, Shakespeare TP
Published 2014-08-01